AZ’4331 is a novel pan-TEAD auto-palmitoylation inhibitor for the treatment of Hippo pathway-altered cancers

Molecular Cancer Therapeutics · Published 2026-07-29 · DOI 10.1158/1535-7163.mct-25-1267

Free full text

Authors (24)

Danielle J. Sanchez, Jacob A. Gordon, Ryan Richards, Erica Banks, Michelle DuPont, Jolanta Dubauskaite, Nicolas Floc’h, Eric Gosselin, Nin Guan, Niresh Hariparsad, Geoffrey A. Holdgate, Clare Hoover, Alex Koers, Matthew J. Martin, Scott Mlynarski, Uthpala Seneviratne, Abhishek Srivastava, Nancy Su, Jan M. Suski, Neil T. Umbreit, Man Xu, Corinne Reimer, Sabina Cosulich, James E. Brownell

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Sanchez, D., Gordon, J., Richards, R., et al. (2026). AZ’4331 is a novel pan-TEAD auto-palmitoylation inhibitor for the treatment of Hippo pathway-altered cancers. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-25-1267

Related articles